Muhıt Özcan

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Laurie H. Sehn, Alex F. Herrera, Christopher R. Flowers et al. · Journal of Clinical Oncology · 2019 · 741 citations · Full text

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

Martin Dreyling, Armando Santoro, Luigina Mollica et al. · Journal of Clinical Oncology · 2017 · 386 citations

Immunology, Pathology, Pi3k Inhibitor +17

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

Philippe Armand, Scott J. Rodig, Catherine Thiéblemont et al. · Journal of Clinical Oncology · 2019 · 256 citations · Full text

ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

Grzegorz S. Nowakowski, Annalisa Chiappella, Randy D. Gascoyne et al. · Journal of Clinical Oncology · 2021 · 252 citations · Full text

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro et al. · The Lancet Oncology · 2021 · 245 citations

Interim Analysis, Lymphoid Neoplasia, Medicine +8